Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
Gastric Cancer · Gastroesophageal Junction Cancer · HER2-positive Gastric Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 82 (final count)
- Started
- Sep 30, 2019
- Main results expected
- Jan 15, 2024
- Fully finished
- Mar 25, 2025
- Results posted
- Apr 22, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Adverse Events of Margetuximab Plus Retifanlimab in Cohort A, as Assessed by CTCAE v5.0
Measured over: Throughout the study, an average of 11 months.
Objective Response Rate (ORR) for Non-microsatellite Instability-high (Non-MSI-H) Participants (Cohort A) Using Investigator-assessed Radiology Reviews
Measured over: Throughout the study, an average of 11 months.
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04082364 · record last updated 2025-06-08 · checked 2026-11-09 15:47 UTC